Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. - Ahrens M; Haanen J; Albiges L; Goupil MG; Boleti E; Gravis G; Fléchon A; Grimm MO; Bedke J; Barthélémy P; Castellano D; Mellado B; et al. (European journal of cancer (Oxford, England : 1990), 2026)